KAUST researchers led by Dr. Niveen Khashab have developed thermosensitive liposomes for controlled drug release, particularly in cancer therapies. The liposomes are designed to release drugs only when they reach heated tumor tissue, minimizing systemic side effects. Cholesterol moieties are used as anchors to create a "nail" or "comb" effect, enabling temperature-triggered drug release inside cells. Why it matters: This targeted drug delivery system could significantly improve the efficacy and reduce the toxicity of cancer treatments.
MBZUAI's Professor Le Song is developing an AI-driven simulation to model the human body at societal, organ, tissue, cellular, and molecular levels. The goal is to reduce the time and cost associated with bringing new medicines to market by removing the need for wet lab biological research. Song aims to create a comprehensive model using machine learning. Why it matters: This research could revolutionize drug discovery in the region by accelerating the development process and reducing reliance on traditional research methods.
MBZUAI's Kun Zhang is applying causal machine learning to improve drug development and precision medicine, focusing on answering 'why' questions. Traditional drug development is costly (est. $2B) due to extensive studies needed to determine drug toxicity and efficacy. Zhang is combining causal ML with organs-on-chips technology to improve pre-clinical drug testing, aiming to reduce the failure rate of drugs in human trials. Why it matters: By improving the accuracy of pre-clinical drug testing, this research could significantly reduce the cost and time required to bring new medicines to market in the region and worldwide.
Shahar Harel, Head of AI at Quris, presented a BIO-AI approach to drug safety assessment using a 'patient-on-a-chip' platform. This platform simulates the human body and generates high-frequency microscopy and biochemical data on drug interactions, considering patient genomics and ethnicity. The data is used to train multimodal deep learning models to predict drug safety and provide patient-specific recommendations. Why it matters: This approach offers a potential alternative to animal models, promising faster and more personalized drug development while reducing safety concerns.
MBZUAI hosted a two-day workshop on "Big Model AI in Drug Design" starting February 20, 2023. The workshop featured presentations from researchers in public and private institutions working on AI and health. MBZUAI Adjunct Professor Eran Segal opened the workshop with a talk on the Human Phenotype Project. Why it matters: The event highlights the growing interest and activity in applying AI, particularly large models, to advance drug discovery and personalized medicine within the UAE's research ecosystem.
A KAUST team developed piRNAi, a gene-silencing tool in nematode worms using synthetic RNA sequences interacting with the piRNA pathway. They successfully silenced genes involved in sex determination and other functions, demonstrating multiplexed gene silencing. The gene silencing lasted for varying durations across generations, up to six generations. Why it matters: This expands the molecular toolkit for gene manipulation and offers potential therapeutic applications in humans, given the presence of the same gene-silencing pathway.
KAUST Ph.D. student Khalil Moussi won two awards at the IEEE International Conference on Nano/Micro Engineered and Molecular Systems for his research on a miniaturized drug delivery system. The system, developed in collaboration with KAIMRC, uses 3D printing and wireless power to deliver drugs for coronary artery disease treatment. The device features an electrochemical micro-pump, a 3D printed reservoir with microneedles, and a wireless powering unit, allowing customization for various in vivo drug delivery applications. Why it matters: This recognition highlights KAUST's contributions to biomedical engineering and its potential to develop innovative solutions for critical healthcare challenges in the region and beyond.
A KAUST alumnus presented research on using large language models for complex disease modeling and drug discovery. LLMs were trained on insurance claims of 123 million US people to model diseases and predict genetic parameters. Protein language models were developed to discover remote homologs and functional biomolecules, while RNA language models were used for RNA structure prediction and reverse design. Why it matters: This work highlights the potential of LLMs to accelerate computational biology research and drug development, with a KAUST connection.